Vericiguat in Combination with Short‐Acting Nitroglycerin in Patients With Chronic Coronary Syndromes: The Randomized, Phase Ib, VENICE Study

Vericiguat is a soluble guanylate cyclase stimulator indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization in adults with symptomatic chronic HF and ejection fraction less than 45%. Guidelines recommend short‐acting nitrates, such as sublingual nitroglycerin, fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Boettcher, Michael, Düngen, Hans‐Dirk, Donath, Frank, Mikus, Gerd, Werner, Nikos, Thuermann, Petra A., Karakas, Mahir, Besche, Nina, Koch, Tanja, Gurniak, Matthias, Becker, Corina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310564/
https://www.ncbi.nlm.nih.gov/pubmed/35258101
http://dx.doi.org/10.1002/cpt.2574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310564/
https://www.ncbi.nlm.nih.gov/pubmed/35258101
http://dx.doi.org/10.1002/cpt.2574

Ejemplares similares